Stealthyx

Developing a unique, safe, patented drug-targeting platform technology...

Stealthyx

...capable of drug delivery only at sites of disease...

Stealthyx

...improving the pharmacokinetic, pharmacodynamic and therapeutic
properties of biological agents

Stealthyx Therapeutics Ltd. is developing a unique, safe, patented drug-targeting platform technology capable of drug delivery only at sites of disease. This will significantly improve the pharmacokinetic, pharmacodynamic and therapeutic properties of biological agents.

THE PLATFORM

The Stealthyx platform is based on a fusion protein between a protective shell-like structure with the pharmacologically active agent linked via an enzyme-sensitive cleavage site. The shell-like structure extends the half-life of the drug by protecting it from interacting with its receptors. The drug gets targeted and delivered to sites of disease and is released by enzymes that are active due to the pathological process.

We have shown that the Stealthyx’s platform delivery provides latency to cytokines, small peptides and antibody fragments. Proof of concept of therapeutic efficacy has been shown in models of human diseases of arthritis, multiple sclerosis, peritonitis, atherosclerosis, cancer and graft-versus-host disease.

Our technology is capable of reducing toxicity of important biological compounds that have been withdrawn from use and has potential applications in many clinical conditions.

Overview of Stealthyx

Stealthyx Therapeutics Ltd has been established to commercialise the intellectual property developed by the group of Professor Yuti Chernajovsky at Barts and The London, School of Medicine and Dentistry, Queen Mary, University of London. The Company's novel delivery platform is underpinned by extensive research programmes over many years funded by the Multiple Sclerosis Society (UK), EU FP6, MRC, BHF, National Multiple Sclerosis Society (USA) and Amgen. Stealthyx secured funding from the Kinetique Biomedical Seed Fund in 2002 and a Translational Award from the Wellcome Trust in 2004.

Recent Series A investment by Index Ventures in 2014 has been a prime milestone for the initiation of the active development of compounds for the treatment of cancer, osteoarthritis and inflammatory autoimmune diseases.

The Stealthyx Concept

Pictured - The Stealthyx platform delivery is formed by a protective shell derived from the latency associated peptide (LAP) of transforming growth factor (TGF) b , a cleavable linker that is sensitive to enzymes found in different pathologies and a drug which is released at the site of disease.

Stealthyx’s platform delivery provides latency to cytokines, small peptides and antibody fragments

Proof of concept of therapeutic efficacy has been shown in models of human diseases of arthritis, multiple sclerosis, peritonitis, atherosclerosis, cancer and graft-versus-host disease

...capable of reducing toxicity of important biological compounds that have been withdrawn from use and has potential applications in many clinical conditions